Bioelectrical Impedance for Self-monitoring of Lymphedema

April 7, 2017 updated by: Sheila Ridner, Vanderbilt University

Bioelectrical Impedance for Self-monitoring of Breast Cancer Related Lymphedema

  • Breast cancer treatment-related lymphedema requires life-long self-care is required.
  • No objective measurement mechanism exists that can easily be used to self-monitor arm volume.
  • Bioelectrical impedance devices approved for lymphedema measurement may be able to be used for self-monitoring.
  • The investigators will conduct a two-part study to first develop an impedance driven self-measurement protocal and then test the protocol in home settings.
  • The investigators hypothesize in part two of the study that when compared to participants who are not self-monitoring, those who self-monitor limb volume will: 1) report more days of garment use, skin care, and simple-MLD; and, 2) have fewer, less distressful, less intense symptoms, better productivity/activity, report higher perceived self-management/self-efficacy and QOL; experience fewer missed days of work, lymphedema treatment days, arm infections, and have a smaller number of antibiotic prescriptions.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Breast cancer treatment-related lymphedema (swelling) is an incurable, chronic condition experienced by a significant percentage of breast cancer survivors. It has many associated symptoms, negatively impacts quality of life (QOL), and increases health care costs. As with other chronic diseases, such as diabetes, life-long self-care is required. No objective measurement mechanism exists that can easily be used to self-monitor arm volume, a key self-care outcome. Those with lymphedema are forced to rely on visual recognition of increasing volume to know if their self-care is effective and when to seek treatment. Timely recognition of worsening swelling is believed to result in better patient outcomes; however, substantial volume increases often occur before observable changes are noted and this window of opportunity is missed. Many with lymphedema only seek care when they have developed infection in the swollen limb.

The inability to objectively monitor arm volume on a regular basis likely results in discomfort, poorer QOL, and increased health care costs.The broad, long-term objective of this application is to develop a method for monitoring arm lymphedema that can be used at home to improve lymphedema self-management and patient outcomes. To accomplish this, the investigators will conduct a two-phase, translational pilot study to explore the use of a hand-held bioelectrical impedance device as an arm volume self-measurement method.

The purpose of Phase 1 is to develop a bioelectrical impedance self-measurement protocol. Healthy volunteers (n=11) and individuals with lymphedema (n=11) will be in Phase 1 (protocol development). This will take place in laboratory and home settings. This Phase is not interventional and is not detailed in this posting.

The purpose of Phase 2 is to compare self-care activities and health and economic outcomes between breast cancer survivors with lymphedema following the self-monitoring protocol developed in Phase 1 and breast cancer survivors with lymphedema not on protocol (n=42).The protocol will be field-tested by breast cancer survivors with lymphedema in Phase 2 (a two group randomized clinical trial). One group will self-measure with impedance at home for three months, weekly record self-care activities, and will complete follow-up assessments. The other group will mirror Group 1 except for impedance measurements. This is an interventional study and is presented as such in this clinical trial posting.

Study Type

Interventional

Enrollment (Actual)

72

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Tennessee
      • Nashville, Tennessee, United States, 37240
        • Vanderbilt Univeristy School Of Nursing

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Healthy Volunteers for Phase 1: no known history of cancer or lymphatic disease.
  2. Lymphedema volunteers Phases 1 &2: history of breast cancer and diagnosis of lymphedema in one arm.
  3. All volunteers: ≥ 21 years of age.

Exclusion Criteria:

  1. Healthy Volunteers Phase 1: history of arm surgery or family history of primary lymphedema.
  2. Lymphedema volunteers Phases 1 & 2: bilateral lymphedema.
  3. All volunteers:

    • inability to stand upright;
    • conditions that could cause swelling: pregnancy, congestive heart failure, liver failure;
    • infection, open sores on arms, or known sensitivity to electrodes;
    • pacemakers or internal defibrillators;
    • currently undergoing IV chemotherapy or radiation; or
    • use of laxatives or diuretics to lose weight.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: self-monitoring
participants will use bioelectrical impedance to self-monitor arm volume at home
bioelectrical impedance
No Intervention: completion of forms
participants will complete self-report forms

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
self care behaviors
Time Frame: 4 months
individual tasks initiated by a participant to care for their lymphedema that may vary from participant to participant.
4 months
Self-care self efficacy
Time Frame: 4 months
perception of abilty to provide lymphedema self-care
4 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
health
Time Frame: four months
lymphedema associated symptoms
four months
quality of life
Time Frame: 4 months
quality of life
4 months
economics
Time Frame: 4 months
expense in terms of lost income or out-of pocket payments related to lymphedema.
4 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2011

Primary Completion (Actual)

December 1, 2012

Study Completion (Actual)

December 1, 2012

Study Registration Dates

First Submitted

April 28, 2011

First Submitted That Met QC Criteria

June 28, 2011

First Posted (Estimate)

June 30, 2011

Study Record Updates

Last Update Posted (Actual)

April 10, 2017

Last Update Submitted That Met QC Criteria

April 7, 2017

Last Verified

April 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 110032

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphedema

Clinical Trials on self-monitor arm volume

3
Subscribe